Design, synthesis, and optimization of new indole acetic acid derivatives as potent and selective CRTH2 receptor antagonists: the discovery of ACT‐774312
作者:Hamed Aissaoui、Martin Holdener、Carmela Gnerre、Kerstin Niggemann、Stefan Reber、Sylvia Richard-Bildstein、Romain Siegrist、Christoph Boss
DOI:10.1002/cmdc.202300007
日期:——
Our endeavor toward the identification of potent and safe CRTH2 receptor antagonists starting from setipiprant (ACT-129968) is reported. An unexpected and surprising discovery was that all unwanted safety issues observed with the very potent antagonist (S)-B-1 (ACT-453859) could be overcome by the replacement of one aromatic CH group by an aromatic nitrogen atom to result in (S)-72 (ACT-774312) which
NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
申请人:AbbVie Inc.
公开号:EP3636643A1
公开(公告)日:2020-04-15
The invention provides compounds of the following formula, pharmaceutically acceptable salts thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
The invention provides compounds of Formula (I)
pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
1-Azakenpaullone, a selective inhibitor of glycogensynthasekinase-3β, was synthesized by carrying out a two-step protocol featuring an indium-trichloride-mediated intramolecular cyclization and mild reaction conditions. The concise synthesis showed significantly improved synthetic efficiency and reduced discharge of waste. We expect the present study to boost the applications of 1-azakenpaullone